Here we provide a molecular explanation for why Ikaros blocks IL-7/STAT5 signaling in pre-B cells during B cell differentiation, and why Ikaros suppresses the tumorigenic effects of constitutively active STAT5 mutations in BCP-ALL [3, 13]. This evidence concerns the gene STAT5B and acute lymphoblastic leukemia.